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Laminin-binding integrins and their
tetraspanin partners as potential
antimetastatic targets
Christopher S. Stipp
Within the integrin family of cell adhesion receptors, integrins a3b1, a6b1, a6b4
anda7b1makeupalaminin-bindingsubfamily.Theliteratureisdividedontherole
of these laminin-binding integrins in metastasis, with different studies indicating
eitherpro-orantimetastaticfunctions.Theopposingrolesofthelaminin-binding
integrins in different settings might derive in part from their unusually robust
associations with tetraspanin proteins. Tetraspanins organise integrins into
multiprotein complexes within discrete plasma membrane domains termed
tetraspanin-enriched microdomains (TEMs). TEM association is crucial to the
strikingly rapid cell migration mediated by some of the laminin-binding
integrins. However, emerging data suggest that laminin-binding integrins also
promote the stability of E-cadherin-based cell–cell junctions, and that
tetraspanins are essential for this function as well. Thus, TEM association
endows the laminin-binding integrins with both pro-invasive functions (rapid
migration) and anti-invasive functions (stable cell junctions), and the
composition of TEMs in different cell types might help determine the balance
between these opposing activities. Unravelling the tetraspanin control
mechanisms that regulate laminin-binding integrins will help to deﬁne the
settings where inhibiting the function of these integrins would be helpful rather
than harmful, and may create opportunities to modulate integrin activity in
more sophisticated ways than simple functional blockade.
Integrins, themajorcellular receptorsforproteins
of the extracellular matrix (ECM), are
heterodimers consisting of one a and one b
subunit. In mammals, eight b subunits and 18 a
subunits combine to create 24 different
heterodimers. Both the a and b subunits
contribute to ligand-binding speciﬁcity (Refs 1,
2). While some integrin subunits pair with only
one partner, others are promiscuous. For
example, the b1 (ITGB1) subunit pairs with the
a1–a11 (ITGA1–11) subunits, as well as av
(ITGAV). The resulting b1 integrins can be
grouped by ligand-binding speciﬁcity. Integrins
a3b1, a6b1 and a7b1 bind laminin isoforms;
integrins a5b1, a8b1 and avb1 bind the Arg-
Gly-Asp (RGD) motif found in ﬁbronectin
(FN1) and other matrix proteins; integrins a4b1
and a9b1 bind the Leu-Asp-Val (LDV) motif
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salso present in ﬁbronectin and other matrix
proteins; and integrins a1b1, a2b1, a10b1 and
a11b1 bind collagens (Refs 1, 2). Several of the
collagen-binding integrins can also recognise
binding sites in certain laminin isoforms, but
for the purpose of this review, laminin-binding
integrins refers to the subfamily containing the
related a3, a6 and a7 subunits.
The data summarised above paint a complex
picture in which many integrins recognise more
than one ligand and many ligands contain
binding sites for more than one integrin. In
addition, they point to a conundrum regarding
the molecular basis of functional diversity
within speciﬁc classes of integrins. Upon ligand
binding, different integrins transduce signals
that differently inﬂuence cell survival,
proliferation, cytoskeletal organisation, cell
adhesion, and migration. Although a few
cytoplasmic effectors have been identiﬁed that
interact with integrin a subunits, the substantial
majority associate directly or indirectly with the
cytoplasmic tails of integrin b subunits (Refs 3, 4).
Thus, a question that arises for b1 integrins
is how so many different heterodimers, each
with a common b1 signalling subunit, are able
to mediate diverse cellular responses to
different ECM proteins.
Here I review how the cell behaviours and
signalling pathways mediated by the a3/a6/a7
laminin-binding integrin subfamily differ from
those mediated by other integrins, and discuss
how these functional and cell biological
differences may relate to the unusual ability of
the laminin-binding integrins to interact with
members of the tetraspanin family of proteins.
The a6 subunit is further distinguished by its
ability to pair with the b4 (ITGB4) subunit. The
unique properties of a6b4 integrin, which
associates with tetraspanins as well, are also
discussed in the review. Tetraspanin association
has signiﬁcant implications not only for the
complex roles the laminin-binding integrins
play in metastasis but also for how these
integrins might ultimately be targeted in
anticancer therapies.
Distinct cell responses mediated
by laminin-binding integrins
Early recognition that cellular responses
mediated by laminin-binding integrins might
be different from those mediated by other
integrins came from studies of neurons. Dorsal
root ganglion and olfactory epithelial neurons
both displayed preferential migration on
laminin isoforms compared with other ECM
proteins, such as collagens and ﬁbronectin
(Refs 5, 6). Moreover, as observed by interference
reﬂectance microscopy, neuronal cells made
fewer and smaller close contacts with laminin
substrates than they did with ﬁbronectin
substrates (Refs 6, 7). The organisation of focal
adhesions – the cytoskeletal and signalling
complexes that form at sites of integrin adhesion
to ECM – also appeared different on laminin:
neurons formed prominent focal adhesions on
ﬁbronectin, but on laminin they formed smaller
and less numerous focal-adhesion-like structures
(Ref. 8).
Morerecently,resultssimilartothosedescribed
for neuronal cells have been obtained for tumour
and epithelial cells. Lung adenocarcinoma cells,
squamous carcinoma cells, and nontransformed
keratinocytes all migrated up to ﬁvefold faster
on laminin isoforms than on other ECM ligands
such as ﬁbronectin or collagen I (COL1A1)
(Refs 9, 10, 11, 12). On ﬁbronectin or collagen I,
cells formed large actin stress ﬁbres and
prominent focal adhesions, while on laminins
fewer stress ﬁbres and smaller, more-peripheral
focal-adhesion-like structures (sometimes termed
‘focal contacts’) were observed (Refs 9, 10, 11).
Thus, data from both neuronal and tumour cell
systems converge on the view that laminin-
binding integrins frequently mediate distinct
cell behaviours typiﬁed by rapid migration,
smaller focal complexes, and fewer actin stress
ﬁbres.
Inprinciple,thefunctional differencesbetween
laminin-binding integrins and other integrins
could result from differences in ligand-binding
afﬁnities. However, the dissociation constants
(Kds) of activated laminin-binding integrins for
different laminin isoforms are in the range of
1–20 nM (Ref. 13), which is similar to the Kd
of activated a5b1 for ﬁbronectin (10 nM)
(Ref. 14), and the Kds of activated a1b1 and
a2b1 for collagen ligands (1–10 nM) (Ref. 15).
Instead, it appears that laminin-binding
integrins may signal differently than other
integrins. In lung adenocarcinoma cells,
adhesion on ﬁbronectin triggered strong
activation of the RhoA (RHOA) small GTPase,
with little activation of the Rac1 (RAC1) small
GTPase (Ref. 9). Conversely a3b1-integrin-
dependent adhesion on laminin-10/11 (termed
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slaminin-511/521 when named according to its
composition of a, b and g chains) triggered Rac
activation with very little concomitant RhoA
activation. In addition, focal adhesion kinase
(FAK/PTK2) activation was signiﬁcantly higher
in cells on ﬁbronectin than in cells on laminin-
10/11 or laminin-5 (laminin-332), while
formation of the trimolecular complex of
p130CAS (BCAR1), CrkII (CRK) and DOCK180
(DOCK1), which promotes Rac1 activation and
cell migration, was much higher on laminin
isoforms than on ﬁbronectin (Ref. 9). Similarly,
a3b1-integrin-dependent adhesion of squamous
carcinoma cells on laminin-5 resulted in less
RhoA activation and enhanced activation of the
small GTPase Cdc42 (CDC42) and its effector
PAK1, compared with cells adherent on
collagen I (Ref. 11).
Collectively, these observations suggest that,
compared with other integrin ligands, cellular
responses to laminin isoforms involve a
different proﬁle of signalling through small
GTPases in the Rho family, which control the
organisation of the actin cytoskeleton.
Signalling through laminin-binding integrins
often features minimal activation of RhoA,
which controls the formation of actin stress
ﬁbres and prominent focal adhesions, and
strong activation of Rac1 and Cdc42, which
control the formation of lamellipodia and
ﬁlopodia, respectively. The result is smaller,
less numerous focal contacts, and a dynamic
actin cytoskeleton oriented towards rapid
migration rather than strong substrate
adhesion.
Withthestrikinglyrapidmigrationthatlaminin
isoforms such as laminin-5 can provoke in vitro,
an attractive hypothesis is that laminin-binding
integrins are poised to be potent mediators of
tumour cell motility, migration and invasion
during metastasis. Indeed, several studies
support the hypothesis that laminin-binding
integrins can have prometastatic functions.
However, the roles of laminin-binding integrins
in metastasis are more complex than such a
straightforward hypothesis would suggest, and,
depending on the context, the laminin-binding
integrins may in fact possess antimetastatic
functions. In the following sections, potential
pro- and antimetastatic functions of the
laminin-binding integrins are discussed, with
an emphasis on in vivo experimental results
and clinical correlations.
Potential roles of a3b1 integrin
in metastasis
Although several studies have identiﬁed a
positive correlation between tumour cell
expression of a3b1 integrin and propensity for
metastasis, a roughly equal number of studies
have reported negative correlations (Table 1).
Moreover, in some cases, such as breast
carcinoma and oral squamous cell carcinomas,
both positive and negative correlations have
been reported. These conﬂicting data suggest
that the role of a3b1 integrin in metastasis may
be highly dependent on context, even within
the same general class of tumours.
Underlying the potential prometastatic
activities of a3b1 integrin might be its ability to
promote adhesion, migration and survival in
response to its ligands laminin-5 and laminin-
10/11, which are present in basement
membranes beneath epithelial or endothelial
cell layers. Indeed, anti-a3-integrin function-
blocking antibodies have inhibited metastatic
cell behaviours in several in vivo models,
including brain colonisation by non-small-cell
lung carcinoma cells inoculated intracardially
(Ref. 16), colonisation by gastric carcinoma after
intraperitoneal implantation (Ref. 17), lung
colonisation by ﬁbrosarcoma cells upon tail-vein
Table 1. Clinical or in vivo experimental
studies reporting correlations between
a3 integrin expression and metastasis
Tumour cell type Refs
Positive correlations
Breast carcinoma 138
Gastric carcinoma 139, 140
Head and neck squamous cell
carcinoma
141, 142, 143,
144
Hepatocellular carcinoma 145
Melanoma 146, 147
Non-small-cell lung cancer 16
Pancreatic adenocarcinoma 148
Negative correlations
Breast carcinoma 149, 150
Colon carcinoma 151, 152, 153
Endometrial cancer 154
Lung adenocarcinoma 155
Oral squamous cell carcinoma 156
Prostate carcinoma 20
Renal carcinoma 21
Testicular seminoma 157
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sinjection (Ref. 18), and invasion of glioma cells
after intracerebral implantation (Ref. 19). The
design of these experiments, in which cells
were treated with antibody once, just prior to
implantation, suggests that acutely blocking
a3b1 function can in some cases inhibit the
ability of circulating tumour cells to adhere,
invade, survive or proliferate at a secondary site.
Howa3b1 mayact in other settingsto suppress
metastasis is not well understood. Although not
typiﬁed by prominent focal contacts, cell–
substrate adhesion mediated by a3b1 could still
in some cases prevent tumour cells from
detaching from the primary tumour site.
Selection of PC-3 prostate carcinoma cells with
enhanced invasive potential yielded a
subpopulation with low expression of a3
integrin, suggesting that reduced a3-dependent
adhesion could promote enhanced mobility in
some settings (Ref. 20). Analysis of renal
carcinoma cells shed from primary tumours
revealed reduced a3 integrin expression on the
circulating tumour cells, suggesting a role for
a3b1 integrin in preventing tumour cell
detachment from the primary tumour in this
model (Ref. 21). The view that a3b1 can act as a
negative regulator of motility gained further
support from the recent analysis of a3-null
keratinocytes, which displayed enhanced
migration in vitro and faster wound healing in
vivo (Ref. 22).
In addition to promoting cell–substrate
adhesion, the antimigratory activity of a3b1
integrin might involve an ability to promote
stable cell–cell junctions. An early study
demonstrated that a3 integrin localises to cell–
cell contact sites in keratinocytes, and that cell–
cell adhesion could be inhibited by an anti-a3
function-blocking antibody (Ref. 23).
Subsequently, it was shown that expression of
a3 integrin, laminin-5, the cell–cell adhesion
protein E-cadherin (CDH1) and the gap-
junctional protein connexin-43 (GJA1) is
coordinately regulated during wound healing,
and that a3-dependent keratinocyte adhesion
on laminin-5 promotes gap-junction formation
(Ref. 24). Concordantly, in kidney epithelial
cells from a3-null mice, E-cadherin localisation
became less well organised, and other adherens
junction components were also displaced,
without removal of E-cadherin from the cell
surface (Ref. 25). The organisation of the
cortical actin cytoskeleton also appeared
altered, with diminished actin at cell–cell
junctions and increased stress ﬁbres at the basal
cell surface. Increased stress-ﬁbre formation
was also observed in basal keratinocytes in the
epidermis of a3-null mice (Ref. 26). Evidence
that a3b1 regulates cell junctions in
transformed cells comes from studies showing
that adhesion on laminin-5 promotes
E-cadherin localisation to cell–cell contact sites
in HT-29 and Caco-2 colon carcinoma cells
(Refs 27, 28). In addition, an anti-a3 function-
blocking antibody perturbed the organisation of
cell–cell contacts in A431 epidermoid
carcinoma cells (Ref. 29).
The junction-stabilising properties of a3b1-
integrin-dependent adhesion on laminin-5
contrast sharply with the junction-destabilising
activity reported for the a2b1-integrin ligand
collagen I (Ref. 30), or the a5b1 and avb3
ligand ﬁbronectin (Ref. 31). In a side-by-side
comparison, Madin–Darby canine kidney
(MDCK) cell scattering triggered by hepatocyte
growth factor (HGF) was supported by collagen
and ﬁbronectin, but attenuated by laminin
(Ref. 32). The breakdown of adherens junctions
triggered by HGF during scattering was found
to be a mechanical phenomenon in which the
strength of cell–substrate traction forces
correlated with the efﬁciency of adherens
junction disruption. The more strongly the cells
were able to pull against their substrate, the
more able they were to physically pull apart the
cell–cell junctions holding them together
(Ref. 32). The reduced scattering observed on
laminin may therefore be related to the
observations discussed above that cell adhesion
on laminin results in fewer actin stress ﬁbres
and smaller focal contacts than adhesion on
other integrin ligands.
Asidefrom actingasanegativeregulatorofcell
motility in some settings, a3b1 integrin may also
have the potential to suppress cell proliferation at
secondary tumour sites. Forced expression of
a3b1 was antiproliferative in squamous
papillomas resulting from a classic two-stage
carcinogenesis protocol (Ref. 33) and in
rhabdosarcoma cells implanted subcutaneously
(Ref. 34). Recent ﬁndings that a3b1 can act as a
regulator of transforming growth factor b1
(TGF-b1/TGFB1) signalling (Refs 35, 36) could
also help to explain the opposing roles of a3b1
in metastatic progression. Like a3b1, TGF-b1
can also display opposing, context-dependent
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sfunctions in tumour progression and metastasis
(Ref. 37).
In summary, the ability of a3b1 integrin to
promote invasion and migration in some
tumours may be balanced by its ability to
promote ‘stay-at-home’ cell–substrate or cell–
cell adhesion or to suppress colonisation at
secondary sites in other cases. Whether
a3b1’s pro- or antimetastatic activities
predominate may depend on additional
factors such as E-cadherin expression status,
passive versus active modes of invasion, or
the array of integrin ligands present at
primary or secondary tumour sites. As
discussed below, the balance between a3b1’s
opposing roles in metastasis might also be
controlled by the complement of a3-associated
tetraspanin proteins present in different
tumour cell types.
Potential roles of a6b4 and a6b1
integrins in metastasis
In contrast to the a3 integrin subunit, whose
expression correlates positively or negatively
with metastasis in roughly equal numbers of
studies, the expression of the a6 integrin
subunit has shown positive correlation in the
majority of reports (Table 2). There have also
been signiﬁcantly more in vivo studies
addressing the functions of a6 integrins in
various models of metastatic cell behaviours
(Table 3). Although a6 can pair with either the
b1o rb4 subunit, the a6b4 heterodimer has
received the most attention by far. Most of the
in vivo studies in Table 3 were performed with
tumour cell types expressing the a6b4
heterodimer, with the virtually unanimous
verdict being that a6b4 integrin has the ability
to act as a promoter of tumour progression and
metastasis. The unique properties of the b4
integrin cytoplasmic tail may be largely
responsible for the a6b4 integrin’s
prometastatic functions.
The structure and function of integrin b4 has
been the subject of several excellent recent
reviews (Refs 38, 39, 40), key points of which
are summarised brieﬂy here. The b4
cytoplasmic tail, which unlike those of other b
integrin subunits is over 1000 amino acids in
length, contains interaction domains for several
proteins. These b4-interacting proteins include
(1) plectin (PLEC1), which links b4 to the
keratin cytoskeleton, (2) the hemidesmosomal
proteins BP180 (COL17A1) and BP230 (DST),
(3) Src (SRC) family kinases, which
phosphorylate multiple tyrosine residues in the
b4 tail, (iv) the adaptor protein Shc (SHC),
which binds to b4 phosphotyrosines and
activates the Ras–MAPK (mitogen-activated
protein kinase) pathway, and (5) 14-3-3 proteins,
which may help promote lateral association of
a6b4 with receptor tyrosine kinases. A primary
physiological role of a6b4 is to organise epithelial
cell hemidesmosomes by binding laminin-5 in the
basement membrane and providing mechanical
linkage to the keratin intermediate network.
Oncogenic activation of signal transduction
pathways can result in tyrosine phosphorylation
of the Shc-binding site of b4a sw e l la sp r o t e i n
kinase C (PKC) phosphorylation of key
serine residues. Collectively, these modiﬁcations
result in disassembly of hemidesmosomes and
mobilisation of signalling-activated a6b4
integrin. Mobilised a6b4 switches from keratin
to actin ﬁlament association and may mediate
migration and invasion on laminin isoforms.
However, many of a6b4’s most potent
prometastatic functions may involve its ability
to act as an ampliﬁer of signalling emanating
from activated receptor tyrosine kinases and
thereby promote tumour cell survival. These
Table 2. Clinical or in vivo experimental
studies reporting correlations between
a6 integrin expression and metastasis
Tumour cell type Isoform Refs
Positive correlations
Breast carcinoma a6b4 and ND
a 158, 159,
160
Colorectal carcinoma a6b4 161
Head and neck
squamous cell
carcinoma
a6b4 and ND 144, 162,
163,
164
Osteosarcoma a6b4 165
Pancreatic cancer a6b1 166, 167
Thyroid carcinoma a6b4 168
Uveal melanoma a6b1 169
Negative correlations
Cutaneous melanoma ND 170
Gastric carcinoma a6b4 139, 171
Ovarian caricinoma ND 172, 173
aND indicates that the identity of the b subunit paired
with a6 was not determined.
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sa6b4-mediated prosurvival functions include
signalling through phosphoinositide 3-kinase
(PI3K) to activate the antiapoptotic serine/
threonine kinase Akt (AKT1) and promote the
expression of vascular endothelial growth factor
(VEGF). VEGF can both stimulate tumour
angiogenesis and exert autocrine effects on the
tumour cells themselves. Many of these
Table 3. In vivo models of metastasis in which a6 integrins were targeted
or manipulated
Tumour type Rodent model Experimental
approach
Outcomes Refs
Breast carcinoma Transgenic; MMTV–
ERBB2 (expressing
activated ERBB2 in
breast epithelium)
Genetic deletion of
the b4 integrin
cytoplasmic tail
signalling domain
Delay in the onset,
growth and metastasis
of breast carcinomas
174
Colon carcinoma
(HT-29 and
variants)
Xenograft;
intracardial or intra-
arterial inoculation
a6o rb4 function-
blocking Abs
Inhibitionoftumourcell
arrestandearlyinvasion
in liver sinusoids
175,
176,
177
Fibrosarcoma
(HT1080)
Xenograft; tail-vein
injection
a6-targeted ribozyme Profoundly reduced
lung colonisation
178
Melanoma
(B16F1)
Isogeneic;
mesenteric vein
inoculation
a6 Ab Reduced tumour cell
extravasation in liver
179
Melanoma
(B16/129)
Isogeneic; tail-vein
injection
a6 Ab Reduced lung
colonisation
180
Melanoma
(MDA-MB-435)
a
Xenograft;
subcutaneous
inoculation
Forced expression of
b4 integrin
Increased
spontaneous
metastasis to lung
181
Osteosarcoma
(MNNG-HOS)
Xenograft; tail-vein
injection
b4 shRNA and
dominant negative b4
Inhibition of lung
colonisation resulting
in prolonged survival
165
Pancreatic
carcinoma
(PaTu 8988t)
Xenograft; tail-vein
inoculation
a6 Ab Reduced lung
colonisation
182
Prostate
carcinoma
(PC3B1)
Xenograft;
intracardial
inoculation
a6Aborexpressionof
a6 mutant
Delayed appearance
and growth of bone
metastasis and
prolonged time to
endpoint
44
Prostate
carcinoma
(PC3N)
Xenograft; bone
implantation
Expression of a6
mutant
Reduced invasion
within the bone
45
Squamous skin
cell carcinoma
Transgenic;
two-stage
carcinogenesis
Forced expression of
a6b4 in suprabasal
keratinocytes
Increased rate of
squamous cell
carcinoma formation,
increased metastases
and reduced survival
time
41
Abbreviations: Ab, antibody; shRNA, short hairpin RNA.
aMDA-MB-435 cells originally believed to be breast carcinoma appear to be melanoma-like.
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sprometastatic functions of a6b4 may occur
independently of laminin binding, reﬂecting the
intrinsic signalling capacity of the b4
cytoplasmic tail. However, a6b4’s ability to
promote tumourigenesis and progression when
transgenically expressed in suprabasal
keratinocytes, as well as its ability to support
the malignant transformation of human
keratinocytes, both depended on binding to
laminin-5 (Refs 41, 42).
The cumulative beneﬁts of mobilised a6b4
integrin for tumour progression may explain
why this integrin (which plays a crucial role in
the maintenance of epithelial structure and thus
might be expected a priori to be a metastasis
suppressor) is maintained or even elevated in
so many carcinomas. Prostate carcinoma is a
notable exception. During prostate cancer
progression, the a6b4 ligand laminin-5 and the
b4 integrin subunit are frequently both
downregulated, with a6 switching to the a6b1
form (Ref. 43). The a6b1 integrin binds to
laminin-10/11, which is present on the surface
of nerves innervating the prostate gland that
may serve as a pathway for tumour cell escape
from the prostate. Laminin-10/11 is also
abundant in the bone matrix, a major site of
prostate cancer metastasis, and antibody
blockade of a6 integrin can inhibit both bone
colonisation and local invasion within the bone
(Refs 44, 45).
Despite the data implicating it in malignant
progression, a6b4 integrin can display tumour-
suppressive activities. In p53 (TP53)-deﬁcient,
transformed keratinocytes, genetic deletion of
a6b4 enhanced tumour formation, growth, and
proliferative index (Ref. 46). However, when the
cells were further transformed with oncogenic
Ras, a6b4 switched roles and became a
promoter of tumour growth. The tumour-
suppressive activity of a6b4 observed in the
absence of oncogenic Ras did not require ligand
engagement, but it was abolished by a point
mutation that disrupted the interaction of the
b4 cytoplasmic tail with the hemidesmosomal
protein plectin (Ref. 46). Thus, the loss of
b4 expression that occurs during the
progression of certain tumour types may be
related to the abrogation of a plectin-dependent
antiproliferative signal. In addition, as
described above for a3b1 integrin, a6b4 can
transduce signals that promote the formation of
E-cadherin-based adherens junctions, with the
potential to restrain tumour cell motility
(Refs 28, 47).
Potential roles of a7b1 integrin in
metastasis
Compared with a3 and a6 integrins, relatively
little is known about the role of a7b1 integrin in
metastasis. Originally identiﬁed in melanoma
cells (Ref. 48) and myoblasts (Ref. 49), the a7
integrin has a relatively restricted physiological
distribution, with prominent expression in
striated and cardiac muscle and certain
endothelial and neuronal cell types (Ref. 50).
Expression of a7 correlates inversely with
metastatic potential in melanoma cells, and
forced expression of a7 in highly metastatic
cells reduced in vitro cell motility, subcutaneous
tumour growth, and lung colonisation after tail-
vein inoculation (Ref. 51). A recent study has
revealed that a7 integrin may act as a tumour
suppressor in a variety of tumour cell types
(Ref. 52). The mechanism underlying the
tumour-suppressive activity of a7b1 remains
unclear, but may involve upregulation of
inhibitors of cyclin-dependent kinases and Rac
family small GTPases (Ref. 52).
Tetraspanin control mechanisms for
laminin-binding integrins
Integrin–tetraspanin complexes
Leaving aside the unique signalling properties of
the b4 integrin subunit, a question that remains
for the other laminin-binding integrins is how
they are able to mediate cellular responses
that, as described earlier, may differ from those
of other b1 integrins. Part of the answer may lie
in the targeting of the laminin-binding
integrins to distinct microdomains on the
plasma membrane deﬁned by the presence of
tetraspanin proteins (tetraspanin-enriched
microdomains or TEMs; Fig. 1).
Tetraspaninsarealargefamilyofproteins(33in
mammals) that are characterised by four
transmembrane domains, cytoplasmic N- and
C-termini, and two extracellular domains (EC1
and EC2). A recent high-resolution cryoelectron
microscopy structure of the tetraspanin-based
urothelial plaques revealed that the smaller EC1
domain packs in under the larger EC2 domain
(Ref. 53), as had been previously predicted by
molecular modelling (Ref. 54). A unique
signature of disulﬁde bonds and a partially
conserved fold within EC2 distinguishes the
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stetraspanin family from other four-pass proteins
(Ref. 55). The X-ray crystal structure of the EC2
domain of tetraspanin CD81 suggested that
CD81 may exist as a homodimer (Ref. 56).
However, the homodimeric interface in the EC2
crystal structure may actually be involved in
intramolecular packing of the EC2 and EC1
domains in intact CD81 (Ref. 54). Nevertheless,
biochemical crosslinking experiments suggest
that tetraspanin homodimers can form, and that
the homodimeric interface may involve
transmembrane domains 1 and 2 (Refs 57, 58).
Tetraspanins heterodimers also occur, as
exempliﬁed by the urothelial plaque
cryoelectron microscopy data (Ref. 53). Polar
amino acid residues within transmembrane
domains 1, 2 and 4, and conserved heptad
repeat sequences in transmembrane domains
1–3 are likely involved in inter- and
intramolecular packing interactions that
support conformational stability, and
homotypic and heterotypic tetraspanin–
tetraspanin interactions (Refs 57, 58, 59). The
simpliﬁed schematic in Figure 1 is not meant to
imply a ﬁxed stoichiometry; rather, except for
specialised cases such as urothelial plaques,
TEMs appear to be both molecularly
heterogeneous [as indicated by ﬂuorescence
deconvolution and immunoelectron microscopy
(Ref. 60)] and highly dynamic [as indicated
by single-particle tracking and sophisticated,
analytical ﬂuorescence techniques (Refs 61, 62,
and reviewed in Ref. 63)].
Membrane-proximal, cytoplasmic cysteine
residues in tetraspanins are modiﬁed by
acylation with palmitic acid. These palmitoyl
residues play a crucial role in maintaining
tetraspanin–tetraspanin associations within
TEMs (Refs 64, 65, 66, 67). In addition, integrin
subunits a3, a6 and b4 are all palmitoylated,
which, at least in the case of the b4 subunit,
may contribute somewhat to integrin–
tetraspanin interactions (Ref. 67). While
palmitoylation is crucial for tetraspanin–
tetraspanin interactions, the primary way by
which laminin-binding integrins are targeted to
TEMs is via direct association with tetraspanin
CD151. The a3 integrin subunit extracellular
domain interacts directly with the EC2 domain
of CD151 in an association that can be captured
by chemical crosslinking and is stable in strong
detergents (Refs 68, 69, 70). In some cell types,
virtually all the a3 integrin is complexed with
CD151 (Ref. 68). The a6 subunit also interacts
directly with CD151 (Ref. 71), but the a6–
CD151 complex may be somewhat less stable in
many cases (Refs 68, 69). Although not as
extensively studied, the association of a7
integrin with CD151 also appears to be a
strong, direct protein–protein interaction
(Ref. 72). CD151 association with the laminin-
binding integrins occurs early in biosynthesis
(Refs 71, 73); thus, CD151 and its integrin
partners most likely trafﬁc together to the cell
surface. Once there, CD151 links the laminin-
binding integrins to other tetraspanins, such as
CD9 and CD81. These other tetraspanins may
in turn have their own major partners (Fig. 1).
For example, CD9 and CD81 associate with two
related immunoglobin superfamily (IgSF)
proteins – EWI-2 (PGRL/CD316/IGSF8) and
EWI-F (CD9P-1/FPRP/PTGFRN) – and link
them via CD151 to a3b1 integrin (Refs 74, 75).
As predicted by the simpliﬁed working model
in Figure 1, genetic ablation or silencing of
CD151 by RNA interference (RNAi) largely
disrupts the association of the laminin-binding
integrins with other TEM-resident proteins such
as CD9 and CD81 (Refs 12, 76, 77, 78), although
some residual CD151-independent associations
may remain.
The EWI proteins serve only as representative
tetraspanin partners in Figure 1. Proteomic and
biochemical analyses have revealed numerous
other TEM-resident proteins, including (1) other
IgSF proteins, such as CD19 and MHC class I
antigen, (2) cell-surface proteases such as
ADAM10, (3) membrane-bound growth factors,
such as HB-EGF (HBEGF), (4) growth factor
receptors, such as the EGF receptor (EGFR), and
(5) other multitransmembrane-domain proteins
such as claudin 1 (CLDN1), the heterotrimeric
G-protein-coupled receptor GPR56, and
putative choline transporters CTL1 (SLC44A1)
and CTL2 (SLC44A2) (Refs 79, 80, 81; see
also the reviews Refs 82, 83). Thus, the
targeting of laminin-binding integrins to TEMs
by CD151 creates many opportunities for
functional collaborations between the integrins
and other cell-surface proteins, or for the
functional modiﬁcation of integrin-mediated
responses.
While the majority of TEM-resident proteins
identiﬁed thus far are transmembrane proteins,
some cytoplasmic components have been
identiﬁed as well (Fig. 1). Classical PKC
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sisoforms PCKa and PCKb (PRKCA and B)
associate with tetraspanins upon activation and
are linked via tetraspanins to laminin-binding
integrins (Ref. 84). Type II phosphatidylinositol
4-kinases (PI4KIIA and B) also associate with
speciﬁc tetraspanins and are thereby linked to
laminin-binding integrins (Refs 68, 85, 86).
Actin-binding ezrin–radixin–moesin (ERM)
family proteins may interact with the
cytoplasmic tails of CD81 and the CD81 partner
proteins EWI-2 and EWI-F, potentially creating
a link between TEMs and the actin cytoskeleton
(Refs 87, 88). Several tetraspanins possess
potential tyrosine-based sorting motifs in their
C-termini (Refs 89, 90). These motifs (of the
form YXXF, where Y represents tyrosine, and F
represents a hydrophobic amino acid) are
recognised by AP adaptor complexes that link
cargo to clathrin in clathrin-coated vesicles. The
YXXF motif in tetraspanin CD63 is recognised
by the m subunit found in the AP-3 (and to a
lesser extent AP-2) complex (Ref. 91), and
mutations in the motif alter the subcellular
localisation of CD63. Syntenin-1 (SDCBP), a
PDZ-domain-containing protein, also binds to
the C-terminus of CD63 and inhibits the AP-2-
dependent internalisation of CD63 from the cell
surface (Ref. 92). In addition, the PDZ-domain
proteins EBP50 (SLC9A3R1) and Sap97 (DLG1)
bind to the CD81 C-terminal tail (Ref. 93).
Several other tetraspanins possess potential
PDZ-domain-binding sites, so it will be
important to determine if other PDZ-domain
proteins also localise to TEMs. Lastly, consistent
Tetraspanin-enriched microdomains
Expert Reviews in Molecular Medicine © Cambridge University Press 2010
Integrin
Other Tspan
partners (e.g.
EWI proteins) Other Tspans
(e.g. CD9, CD63,
CD81, CD82)
Tspan
CD151
PI4KII
PKC
PDZ
Actin
C
EC2
EC1
Polar amino acid
ERM AP
Palmitoyl group
α β
N
Figure 1. Tetraspanin-enriched microdomains. Laminin-binding integrins associate directly with tetraspanin
CD151 and are linked to other tetraspanins (such as CD9, CD63, CD81 and CD82) and tetraspanin partner
proteins, such as the immunoglobulin superfamily proteins EWI-2 and EWI-F (the EWI proteins). Cytoplasmic
effectors associated with tetraspanin-enriched microdomains (TEMs) include type II phosphatidylinositol 4-
kinases (PI4KIIs), classical protein kinase C (PKC) isoforms, ezrin–radixin–moesin family proteins (ERMs),
and AP adaptor proteins (APs). Key structural features of tetraspanins include large and small extracellular
domains (EC2 and EC1, respectively), polar amino acid residues within transmembrane domains 1, 3 and 4,
and palmitoylation of intracellular cysteine residues.
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swith the association of heterotrimeric G-protein-
coupled receptors with tetraspanins,
heterotrimeric G proteins themselves have also
been detected in tetraspanin complexes
(Refs 80, 94) (not shown in Fig. 1).
Numerous studies indicate that the localisation
of laminin-binding integrins to TEMs is functionally
relevant. Antitetraspanin antibodies, forced
expression of tetraspanin mutants, genetic
deletion, and RNAi-mediated silencing of
tetraspanin expression have all produced
examples in which the function of laminin-
binding integrins has been compromised (see
Refs 82, 95, 96). Nevertheless, the molecular
mechanisms by which tetraspanins regulate
integrin function remain murky. The sections
below highlight potential tetraspanin control
mechanisms for laminin-binding integrins that
have emerged from recent studies.
Do tetraspanins regulate integrin–ligand
interactions?
Twostudieshaveproposedthattetraspaninsmay
regulate integrin–ligand binding by regulating
integrin afﬁnity state. In one study, a soluble
a5b1-integrin-ligand mimetic (RGD peptide)
was added to parental Chinese hamster ovary
(CHO) cells or to a CHO cell subclone
overexpressing CD9 (Ref. 97). The binding of an
anti-b1-integrin antibody that recognises a
ligand-induced binding site (LIBS) epitope was
then assessed by ﬂow cytometry. The apparent
upregulation of the LIBS epitope on the CD9-
overexpressing cells in response to RGD was
modestly higher than that of the parental CHO
cells. However, because the CD9–a5b1
association can be observed only in very mild
detergents (Ref. 98), it may be indirect, raising
the question of how CD9 could directly
modulate the a5b1 afﬁnity state. An alternative
explanation is that CD9 expression could
change the clustering or organisation of a5b1
on CHO cells thereby improving the avidity of
the bivalent LIBS antibody used in this study.
In the other study, a preparation of a3b1
integrin apparently depleted of associated
CD151 was compared with non-CD151-
depleted a3b1 upon reconstitution into
liposomes (Ref. 99). The CD151-depleted a3b1
liposomes bound somewhat less well to
laminin-10/11 compared with nondepleted
liposomes. The CD151-depleted liposomes also
showed reduced binding to wells coated with
an anti-b1-integrin-LIBS antibody. Adding back
CD151 to the CD151-depleted liposomes
restored their binding to laminin-coated wells
to normal levels. These results were interpreted
as evidence that CD151 might stabilise the
activated, ligand-bound conformation of a3b1
integrin, but other interpretations are possible.
Given the ability of tetraspanin proteins to self-
associate, increasing CD151 content in
liposomes might create clusters or patches
containing higher densities of a3b1, enhancing
its avidity for physiological or nonphysiological
ligands. This issue might not be fully resolved
until monovalent, soluble ligand mimetics are
available that can detect preconﬁgured,
activated laminin-binding integrins in the way
that, for example, Fab fragments of the WOW-1
antibody can detect activated b3 integrins
(Ref. 100). Of potential relevance, CD151
regulates post-ligand-binding signalling events
mediated by aIIbb3 integrin in platelets
without inﬂuencing ligand binding itself
(Ref. 101). Thus, at least in this case, it appears
that CD151 does not act by regulating the
afﬁnity state of its integrin partner.
Some studies have reported that genetic
deletion or RNAi-mediated silencing of CD151
results in reduced adhesion on laminin
isoforms (Refs 12, 78, 99, 102, 103). However,
others have reported no difference in short-
term adhesion assays for CD151-depleted cells
(Ref. 77). Reduced adhesion should not be
construed as evidence for reduced integrin–
ligand binding afﬁnity. Adhesion differences
in such assays more likely reﬂect impaired
kinetics of cell spreading on laminin, which is
a generally agreed outcome of silencing or
deleting CD151 (Refs 12, 77, 102, 103).
Whether or not a difference in adhesion is
observed may depend upon detachment force
or ligand density, which may vary from one
study to another.
Spreading defects in CD151-silenced cells may
be related to the role of CD151 in promoting
adhesion strengthening – the increase in
resistance to detachment that follows initial
adhesion (Ref. 104). The mechanisms of
adhesion strengthening are unclear but may
involve several factors, including a progressively
increasing area of cell–substrate attachment,
recruitment of additional integrins to
attachment sites, force-dependent integrin
activation, and increased strength of the
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sintegrin–cytoskeleton interaction such that
membrane stiffness in the vicinity of ligated
integrins increases (Refs 105, 106). The potential
for TEMs to provide auxiliary links to the actin
cytoskeleton via ERM proteins or scaffolds
organised by PDZ-domain proteins may thus
be of relevance (Fig. 1). In this regard, it is
interesting to note that a CD151 C-terminal
cytoplasmic tail mutant was defective in its
ability to promote a6b1-integrin-dependent
adhesion strengthening (Ref. 104). Tetraspanin
association might also facilitate the recruitment
of laminin-binding integrins into adhesive
nanoclusters, as has been described for the
cell adhesion molecules VCAM and
ICAM, which associate with tetraspanins in
endothelial cells (Ref. 61). A similar role has
been proposed for tetraspanin CD81, which
promotes adhesion strengthening mediated by
its partner a4b1 integrin under shear-ﬂow
conditions (Ref. 107).
Tetraspanin regulation of integrin
trafﬁcking
A variety of studies show that tetraspanins can
regulate the trafﬁcking of their partners
(reviewed in Refs 90, 95). In CD151-silenced
carcinoma cells migrating on laminin-5, the rate
of a3 integrin internalisation was signiﬁcantly
impaired compared with wild-type cells
(Ref. 12). Concurrently, persistent protrusions
formed at lateral and trailing edges of the
migrating tumour cells. Since continuous
forward migration depends not only on the
formation of new adhesive contacts at the front
of the cell but also the disassembly of old
adhesive contacts at the rear, one way that
tetraspanin association might facilitate the rapid
migration mediated by laminin-binding
integrins is by promoting efﬁcient integrin
internalisation at the lateral or trailing edges of
migrating cells. Different complements of
tetraspanins might inﬂuence integrin trafﬁcking
in different cell types. For example, enforced
expression of tetraspanin CD82 in Du145
prostate carcinoma cells reduced a6 integrin
cell-surface expression, enhanced ligand-
induced a6 internalisation, and impaired a6-
dependent adhesion and morphogenesis
(Ref. 108). However, cell-surface a6 was not
altered upon CD82 expression in PC-3 prostate
carcinoma cells (Ref. 109), so the effect of CD82
on integrin cell-surface expression is different in
different cell types. Mutation of the YXXF motif
in the CD151 C-terminal cytoplasmic tail
strongly inhibited CD151 internalisation from
the cell surface, suggesting that this motif,
which might interact with AP adaptor proteins
(Fig. 1), could be important for regulating
integrin trafﬁcking (Ref. 110). However, no
difference in the internalisation rate of total cell-
surface a6 integrin was observed in cells
overexpressing the CD151 YXXF mutant, so the
magnitude of its impact on integrin trafﬁcking
remains to be determined. In addition, the
CD82 YXXF motif appears not to mediate an
association with the AP-2 adaptor complex, and
may not be required for CD82 internalisation
(Ref. 111). Thus, the functionality of the putative
YXXF motifs is different for different
tetraspanins.
Tetraspanin regulation of integrin
signalling
In several independent studies, RNAi-mediated
silencing or genetic deletion of tetraspanin
CD151 has resulted in impaired signalling
through laminin-binding integrins (Refs 76, 77,
78, 112). Signalling molecules whose activities
were reduced in CD151-deﬁcient cells include
tyrosine kinases FAK, Src and Lck (LCK),
serine/threonine kinases Akt and ERK
(MAPK1), and small GTPases Rac1 and Cdc42.
Reduced activation of nitric oxide synthase
(eNOS, NOS3) and reduced phosphorylation of
the focal adhesion scaffold protein paxillin
(PXN) have also been reported. In addition,
enforced CD82 expression inhibited integrin-
dependent crosstalk with the c-Met (MET)
receptor tyrosine kinase and Src signalling
through the Src substrates FAK and p130CAS,
an adaptor protein important for integrin-
driven cell motility (Ref. 109). CD82 expression
might also inﬂuence the outright expression
level of p130CAS and thus p130CAS-dependent
signalling (Ref. 113).
Collectively, these data indicate that
tetraspanin association makes critical
contributions to signalling through laminin-
binding integrins. However, it remains to be
established whether tetraspanin association is
simply required for laminin-binding integrins
to signal properly or whether tetraspanins
endow laminin-binding integrins with some of
the unique properties that distinguish them
from other integrins. As discussed in preceding
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ssections, cells adhering on laminins may display
less activation of the small GTPase RhoA, fewer
actin stress ﬁbres, smaller focal adhesions, and
enhanced stability of cell–cell junctions,
compared with cells adhering on other integrin
ligands. Do tetraspanins contribute to any of
these special properties? Support for the
possibility that they do comes from a recent
study of A431 epidermoid carcinoma cells,
which deposit and adhere to their own laminin-
5-rich matrix and normally display relatively
orderly cell–cell junctions. Near-total RNAi-
mediated silencing of CD151 in A431 cells
resulted in signiﬁcantly elevated RhoA activity,
increased actin stress ﬁbres, disorganised
adherens junctions, and a more highly dynamic
monolayer with a reduced lifespan of cell–cell
contacts (Ref. 114). Treating cells with a cell-
permeable RhoA inhibitor or re-expressing
wild-type CD151 in the silenced cells reversed
these phenotypes, but re-expressing a CD151
mutant with impaired a3b1 integrin association
did not. These data suggest that upon loss of
CD151 association, a3b1 may lose some of the
unique functions that set it apart from the non-
laminin-binding integrins. Supporting these
observations, silencing CD151 in HSC5
epidermal carcinoma cells or in embryonic
kidney cells also resulted in elevated stress-ﬁbre
formation (Refs 103, 115), and forced expression
of a CD151 palmitoylation mutant disrupted
a3b1 integrin association with other
tetraspanins and increased the size of focal
adhesions in Rat-1 ﬁbroblasts plated on
laminin-5 (Ref. 116). In addition, an a3 mutant
with impaired association with CD151 failed to
rescue the disturbed cell–cell junctions
observed in a3-null kidney epithelial cells
(Ref. 115).
Figure 2 depicts a working model based on the
observations above. Laminin-binding integrins
associate with tetraspanin CD151 early in
biosynthesis, resulting in delivery of the
integrins to TEMs on the cell surface.
Tetraspanin association may allow laminin-
binding integrins to organise smaller, more-
promigratory focal contacts than other
integrins. Tetraspanins also contribute to
signalling events required for rapid cell
migration and may facilitate disassembly and
recycling of old adhesive contacts. Collectively,
these functions support rapid tumour cell
migration, invasion and metastasis. Balancing
these promigratory functions, tetraspanin
association may also allow the laminin-binding
integrins either to generate a Rho-suppressive
signal or to avoid activating Rho to the same
extent as other integrins, resulting in a low
basal level of Rho activity compatible with
stable adherens junctions. E-cadherin itself may
also participate in these Rho-suppressive
functions (Ref. 117). Stable cell–cell junctions
may function to oppose tumour cell migration
and invasion. Such an arrangement could help
to explain the divided literature on the roles of
laminin-binding integrins in metastasis.
Depending on which aspect of their
tetraspanin-controlled functions predominates
in a particular setting, laminin-binding
integrins could function as either promoters or
suppressors of metastasis. The tetraspanin
expression proﬁles in different cell types could
help determine which functions predominate.
For example, tetraspanins CD9 and CD82 have
been implicated both as promoters of junctional
organisation (Refs 118, 119) and as suppressors
of tumour cell motility (Refs 120, 121). Thus,
CD9 and CD82 may tilt the scale of laminin-
binding integrin function towards the
metastasis-suppressive side, possibly helping to
explain why these tetraspanins have frequently
been implicated as metastasis suppressors
(Refs 120, 121). The unique properties of a6b4
integrin, both in terms of its ability to organise
hemidesmosomes in stable epithelia and in
terms of the potent, b4-dependent,
prometastatic signalling functions that can be
unleashed during carcinoma progression, may
not ﬁt neatly into the working model shown in
Figure 2. However, CD151 association is known
to contribute to a6b4’s promigratory functions
(Ref. 76), and has been proposed to contribute
to its hemidesmosomal functions as well
(Ref. 122).
Possible clinical implications and
outstanding questions
Laminin-binding integrins and their tetraspanin
partners might be targeted by a variety of
approaches including function-modulating
monoclonal antibodies, RNAi-based
therapeutics, and, in the case of tetraspanin
proteins, recombinant soluble EC2-domain
mimics. Current prospects for development of
these different interventions to the stage of
clinical trials have been recently reviewed
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selsewhere (Ref. 123). The discussion here
focuses on gaps in our knowledge that need to
be ﬁlled to support the clinical use of reagents
targeting laminin-binding integrins and
tetraspanins, as more such reagents become
available.
Should the laminin-binding integrins
be directly targeted?
The laminin-binding integrins have important
developmental and tissue-maintenance
functions, so the possibility of directly targeting
them in cancer with function-blocking or
Consequences of TEM localisation for laminin-binding integrins
Expert Reviews in Molecular Medicine © Cambridge University Press 2010
Adherens
junction
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Figure 2. Consequences of TEM localisation for laminin-binding integrins. Laminin-binding integrins
(represented by a3b1) associate with tetraspanin CD151 via a direct protein–protein interaction between the
a integrin subunit ectodomain and the CD151 EC2 domain. The integrin–CD151 complex forms early in
biosynthesis and is delivered to cell-surface tetraspanin-enriched microdomains (TEMs). TEM localisation
may promote a3b1-dependent tumour cell migration on laminin-5 in multiple ways including (1) facilitating
the formation of small, promigratory focal contacts, (2) participating in promigratory signalling, and
(3) facilitating efﬁcient internalisation of a3b1 at the trailing edge of migrating cells. TEM localisation may
also allow a3b1 to collaborate with E-cadherin to reduce the activity of the RhoA small GTPase to a low
basal level. Too much RhoA activity can destabilise adherens junctions, which normally function to restrain
tumour cell motility. Thus, by keeping RhoA activity low, a3b1–tetraspanin complexes might exert an
antimigratory activity that balances a3b1’s promigratory functions.
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sexpression-blocking therapeutics will likely
depend upon the ability to deliver the
therapeutic speciﬁcally to tumour cells.
Assuming that this technical hurdle can
eventually be overcome, the question remains
‘under what circumstances would it be
advantageous to extinguish laminin-binding
integrin function in tumour cells?’ Thus far,
available data on a6b4 integrin from in vivo
models (Table 3) suggest that for tumours
bearing signalling-activated, mobilised a6b4
integrin, blocking its function would in most
cases be beneﬁcial. There may be exceptions,
such as certain gastric carcinomas, in which
a6b4 may play a suppressive role (Table 2). In
addition, analysis of a6b4 in transformed
keratinocytes suggests that blocking its function
in early-stage tumours might in some cases be
counterproductive (Ref. 46). For a3b1 integrin,
the situation may be more complex. As the
studies summarised in Table 1 and the working
model in Figure 2 both emphasise, a3b1’s
function in tumour progression is likely to be
highly dependent on context. For example, in
situations where a3b1 is making a strong
contribution to the maintenance of stable cell–
cell junctions, blocking its function might result
in a more invasive phenotype rather than
reduced invasion. Thus, the role of a3b1 may
depend upon factors such as E-cadherin
expression status or the complement of
tetraspanin proteins present in speciﬁc
tumours. For a7b1 integrin, the relatively
limited data available indicate that it plays a
tumour-suppressive role in multiple tumour
cell types (Ref. 52).
An alternativetoblockingor silencing laminin-
binding integrins would be to modify their
function. Thus far, no a-integrin-subunit-
speciﬁc activating antibodies have been
reported; however, an antimetastatic a6 integrin
antibody that inhibits regulated ectodomain
cleavage of the a6 subunit (but not a6-
dependent adhesion) has recently been
described (Ref. 44). In addition, an anti-a3-
integrin antibody that does not block adhesion
has been reported to block keratinocyte
migration on laminin-5 (Ref. 124). It might be
beneﬁcial to re-evaluate the activities of the
wealth of available anti-integrin antibodies, in
light of the more sophisticated knowledge of
integrin function that has accumulated since
many of these reagents were ﬁrst generated.
The numerous associations of the b4 integrin
subunit with receptor tyrosine kinases and
intracellular signalling proteins might create the
potential for targeting b4 signalling functions
without disrupting b4-dependent adhesion
(Ref. 39). Mice bearing a b4 subunit with
impaired signalling functions are viable and
fertile (Ref. 125), suggesting that inhibitors of
b4 signalling might not disrupt critical
physiological functions.
Prospects for modulating laminin-binding
integrin function by targeting TEMs
Since its identiﬁcation as a major, directly
interacting partner of the laminin-binding
integrins, CD151 has received signiﬁcant
attention as a potential therapeutic target in
cancer. Increased CD151 expression correlates
with increased risk of metastasis or reduced
survival in colon, lung and prostate cancers
(Refs 126, 127, 128). Elevated CD151 expression
is also observed in some breast cancers and
correlates with reduced survival in breast
cancer patients (Refs 76, 112). RNAi-mediated
silencing of CD151 slowed the growth of
orthotopic or subcutaneously xenografted
MDA-MB-231 breast carcinoma cells (Refs 76,
112). In addition, an anti-CD151 monoclonal
antibody strongly inhibited spontaneous
metastasis in a chick embryo xenograft model
(Ref. 129). Collectively, these studies have
established CD151 as a potentially attractive
target; however, several important questions
remain. First, while it is clear that loss of CD151
can impair the functions of laminin-binding
integrins, it is not yet known whether this is the
basis of the reduced in vivo growth rate of
CD151-silenced tumour cells. Similarly, the
antimetastatic CD151 antibody inhibits tumour
cell intravasation by suppressing cell–matrix
detachment at the trailing edge of migrating
cells (Ref. 129), but it is not clear which
integrins are involved in this effect. In addition,
kidney failure in human patients and mice
lacking CD151 suggests that, as with the
laminin-binding integrins themselves, targeting
CD151 may require tumour-speciﬁc delivery of
the therapeutic agent (Refs 130, 131, 132).
Lastly, if the working model in Figure 2 holds,
additional factors, such as E-cadherin
expression status, may determine in which
cases CD151 targeting may be beneﬁcial. In this
regard, the MDA-MB-231 tumour cell line,
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swhich is the only tumour cell type used thus far
for in vivo tumour growth assays after CD151
silencing, lacks E-cadherin expression.
Additional experiments with E-cadherin-
positive tumour cells may provide important
information about the diversity of CD151’s
functions in tumour progression. The recent
identiﬁcation of DHHC2 (ZDHHC2), an
enzyme responsible for palmitoylation of the
CD151 (and CD9) cytoplasmic tail, may
represent another way in which CD151 function
could be modulated (Ref. 133). However, RNAi
inhibition of DHHC2 disrupted E-cadherin-
based carcinoma cell–cell junctions (Ref. 133). If
the loss of junctions in DHHC2-depeleted cells
turns out to be a tetraspanin-dependent
phenomenon, it would serve to further
underscore the complex roles of integrin–
tetraspanin complexes in regulating tumour
cell–cell and cell–substrate interactions.
Like CD151, TSPAN8 (CO-029) has been
implicated as a promoter of metastasis, and
part of TSPAN8’s prometastatic functions may
come from its ability to associate with a6b4
integrin via CD151 and promote a6b4-
dependent migration and metastasis (Ref. 120).
TSPAN8 plays an important role in pancreas
development in Xenopus embryos (Ref. 134), but
its functions in mammalian development and
adult physiology are not well deﬁned, so the
extent to which targeting TSPAN8 in tumours
might cause undesirable side effects in normal
tissues remains unknown.
An alternative to inhibiting the tumour-
promoting functions of tetraspanins such as
CD151 and TSPAN8 would be to somehow take
advantage of the tumour-suppressive functions
of tetraspanins such as CD9 and CD82. Proof of
principle for such an approach comes from the
demonstration that intratracheally instilled
adenoviral vectors encoding CD9 or CD82
could suppress lymph-node metastases of
orthotopically implanted Lewis lung carcinoma
cells (Ref. 135). Since many tumours might not
be as amenable to adenoviral delivery, another
approach would be to identify small-molecule
therapeutics that promote CD9 or CD82
expression. For example, CD82 is targeted for
degradation by the ubiquitin E3 ligase gp78
(AMFR), and suppressing gp78 expression by
RNAi enhanced CD82 expression and blocked
pulmonary metastasis of ﬁbrosarcoma cells
(Ref. 136). Thus, selective small-molecule
inhibitors that target speciﬁc components of the
ubiquitin–proteasome system, such as
individual E3 ligases (Ref. 137), might be
screened for their effects on tetraspanin
expression. Lastly, while there is signiﬁcant
evidence that CD9 and CD82 can both inﬂuence
cell motility, it still remains unclear whether
this is the primary mode by which they exert
antimetastatic effects (Refs 120, 121). More
structure–function studies coupled with in vivo
metastatic colonisation assays are needed to
address this question.
Conclusion
The laminin-binding integrins are potential
therapeutic targets for inhibition of metastasis,
but they also fulﬁl critical physiological
functions in the organisation and maintenance
of epithelial cell layers. Tetraspanin proteins
may offer the potential to modulate the
functions of laminin-binding integrins in more
subtle ways, with less likelihood of disrupting
key physiological functions. Important
outstanding questions include deﬁning in
which settings the laminin-binding integrins are
acting as promoters versus suppressors of
metastasis, and clarifying the molecular
mechanisms by which tetraspanins regulate
integrin function. Advances in the clinical use
of RNAi and the development of small-molecule
inhibitors that can modulate tetraspanin
expression or function may bring with them the
promise of ﬁnally unlocking the therapeutic
potential of the laminin-binding integrins.
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Further reading, resources and contacts
Ya ´n ˜ez-Mo ´, M. et al. (2009) Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes.
Trends in Cell Biology 19, 434-446
This is an up-to-date review on tetraspanin-enriched microdomains, with an emphasis on new data emerging
from sophisticated live cell imaging techniques.
Charrin, S. et al. (2009) Lateral organization of membrane proteins: tetraspanins spin their web. Biochemical
Journal 420,133-154
The article provides a comprehensive review of tetraspanin biochemistry, structure and function.
Zo ¨ller, M. (2009) Tetraspanins: push and pull in suppressing and promoting metastasis. Nature Reviews Cancer
9, 40-55
This reviews integrin-dependent and -independent mechanisms by which tetraspanins might inﬂuence
metastasis, including the presence of tetraspanins in exosomes (30–100 nm vesicles released by many
cell types) – a topic not extensively discussed elsewhere.
Miranti, C.K. (2009) Controlling cell surface dynamics and signaling: how CD82/KAI1 suppresses metastasis.
Cell Signalling 2009, 21:196-211
This is an in-depth review of CD82, a tetraspanin with long-standing recognition as a metastasis suppressor.
Hemler, M.E. (2008) Targeting of tetraspanin proteins–potential beneﬁts and strategies. Nature Reviews Drug
Discovery 7, 747-758
This review analyses potential strategies for targeting tetraspanin proteins in cancer and other diseases.
Berditchevski, F . and Odintsova, E. (2007) Tetraspanins as regulators of protein trafﬁcking. Trafﬁc 8, 89-96
The article reviews evidence that tetraspanins regulate the trafﬁcking of their protein partners and the
mechanisms involved.
Features associated with this article
Figures
Figure 1. Tetraspanin-enriched microdomains.
Figure 2. Consequences of TEM localisation for laminin-binding integrins.
Tables
Table 1. Clinical or in vivo experimental studies reporting correlations between a3 integrin expression and
metastasis.
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sFeatures associated with this article (continued)
Table 2. Clinical or in vivo experimental studies reporting correlations between a6 integrin expression and
metastasis.
Table 3. In vivo models of metastasis in which a6 integrins were targeted or manipulated.
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